{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T11:20:18Z","timestamp":1709810418866},"reference-count":39,"publisher":"Hindawi Limited","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2723,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2008.01736.x","type":"journal-article","created":{"date-parts":[[2008,3,19]],"date-time":"2008-03-19T02:54:17Z","timestamp":1205895257000},"page":"723-728","source":"Crossref","is-referenced-by-count":12,"title":["High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study"],"prefix":"10.1155","volume":"62","author":[{"given":"V.","family":"Barrios","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"De La Figuera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Honorato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"Llisterri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Calder\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2008,3,18]]},"reference":[{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/bmj.38766.624097.1F","article-title":"Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study","volume":"332","author":"Sundstrom","year":"2006","journal-title":"BMJ"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2006.01.008","article-title":"Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns","volume":"119","author":"Haffner","year":"2006","journal-title":"Am J Med"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic","volume":"414","author":"Zimmet","year":"2001","journal-title":"Nature"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.amjhyper.2006.09.010","article-title":"Age and target organ damage in essential hypertension: role of the metabolic syndrome","volume":"20","author":"Cuspidi","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2006.09.032","article-title":"Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies","volume":"49","author":"Gami","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1524-6175.2006.04716.x","article-title":"The metabolic syndrome and its relationship to hypertensive target organ damage","volume":"8","author":"Mule","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.jhh.1002203","article-title":"Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study","volume":"21","author":"De Simone","year":"2007","journal-title":"J Hum Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"Guidelines for the management of arterial hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1559-4564.2007.06313.x","article-title":"Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis","volume":"2","author":"Barrios","year":"2007","journal-title":"J Cardiometab Syndr"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2165\/00003495-200363220-00013","article-title":"Lercanidipine: a review of its efficacy in the management of hypertension","volume":"63","author":"Bang","year":"2003","journal-title":"Drugs"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/08037050211265","article-title":"Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study","volume":"11","author":"Barrios","year":"2002","journal-title":"Blood Press"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00005344-200207000-00016","article-title":"Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension","volume":"40","author":"Viviani","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1742-1241.2006.01176.x","article-title":"Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA study","volume":"60","author":"Barrios","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB15|cit15","first-page":"433","article-title":"The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LERZAMIG study","volume":"13","author":"Barrios","year":"2006","journal-title":"Br J Cardiol"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2217\/14750708.4.4.433","article-title":"Antihypertensive effectiveness of lercanidipine administered using an electronic pillbox compared with usual care in a cohort of mild-to-moderately hypertensive patients: the ELECTRA study","volume":"4","author":"Barrios","year":"2007","journal-title":"Therapy"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/sj.jhh.1001430","article-title":"A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension","volume":"16","author":"James","year":"2002","journal-title":"J Hum Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.jhh.1001614","article-title":"Lercanidipine vs. lacidipine in isolated systolic hypertension","volume":"17","author":"Millar-Craig","year":"2003","journal-title":"J Hum Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/01.hjh.0000198987.34588.11","article-title":"Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension","volume":"24","author":"Agrawal","year":"2006","journal-title":"J Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0895-7061(02)03000-5","article-title":"Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives","volume":"15","author":"Leonetti","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1081\/JDI-42801","article-title":"Lercanidipine in patients with chronic renal failure: the ZAFRA study","volume":"27","author":"Robles","year":"2005","journal-title":"Ren Fail"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB22|cit22","doi-asserted-by":"crossref","DOI":"10.1111\/j.1527-3466.2007.00035.x","article-title":"Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice. The TOLERANCE Study","author":"Barrios","year":"2008","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","article-title":"European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension","volume":"21","author":"European Society of Hypertension-European Society of Cardiology Guidelines Committee","year":"2003","journal-title":"J Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB25|cit25","first-page":"69","article-title":"The interpretation of diagnostic data","author":"Sackett","year":"1991","journal-title":"Clinical epidemiology: a basic science for clinical medicine"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/sj.jhh.1002167","article-title":"Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study","volume":"21","author":"Barrios","year":"2007","journal-title":"J Hum Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1157\/13086123","article-title":"Prevalence and general features of the metabolic syndrome in the Spanish hypertensive population","volume":"126","author":"De la Sierra","year":"2006","journal-title":"Med Clin (Barc)"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1097\/HJH.0b013e32829fb3ec","article-title":"Evolution of blood pressure control in Spain","volume":"25","author":"Barrios","year":"2007","journal-title":"J Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB30|cit30","first-page":"8","article-title":"Drug treatment of hypertension: compliance and adverse reactions in a cohort of hypertensive patients in a primary care setting","volume":"59","author":"Mino-Le\u00f3n","year":"2007","journal-title":"Rev Invest Clin"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(98)09103-X","article-title":"Application of evidence from randomised controlled trials to general practice","volume":"353","author":"Rosser","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/archinte.167.1.68","article-title":"External validity of clinical trials in acute myocardial infarction","volume":"167","author":"Steg","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1517\/13543784.8.7.1043","article-title":"Lercanidipine: a novel lipohilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity","volume":"8","author":"Meredith","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1211\/0022357991772844","article-title":"Vascular-selective effect of lercanidipine and other 1,4 dihydropyridines in isolated rabbit tissues","volume":"51","author":"Angelico","year":"1999","journal-title":"J Pharm Pharmacol"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/00004872-200305000-00026","article-title":"Quantification of leg oedema in post-menopausal hypertensive patients treated with lercanidipine or amlodipine","volume":"21","author":"Lund-Johansen","year":"2003","journal-title":"J Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0895-7061(03)00901-4","article-title":"Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension","volume":"16","author":"Fogari","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB37|cit37","first-page":"1357","article-title":"Different behaviour of the sympathetic responses to acute and chronic blood pressure reductions induced by antihypertensive drugs","volume":"16","author":"Grassi","year":"1998","journal-title":"J Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/08038020310000087","article-title":"Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial","volume":"1","author":"Borghi","year":"2003","journal-title":"Blood Press Suppl"},{"key":"10.1111\/j.1742-1241.2008.01736.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1543-5946(05)80026-1","article-title":"Self-reported medication use in community-residing older adults: A pilot study","volume":"3","author":"Roth","year":"2005","journal-title":"Am J Geriatr Pharmacother"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2008.01736.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2008.01736.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:05:54Z","timestamp":1643349954000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2008.01736.x"}},"subtitle":["Metabolic syndrome and high doses of lercanidipine"],"short-title":[],"issued":{"date-parts":[[2008,3,18]]},"references-count":39,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01736.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3,18]]}}}